These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 37064132)

  • 21. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
    Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
    Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC.
    Mahmoudian RA; Mozhgani S; Abbaszadegan MR; Mokhlessi L; Montazer M; Gholamin M
    J Mol Histol; 2021 Jun; 52(3):597-609. PubMed ID: 33884540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble Immune Checkpoint-Related Proteins in Blood Are Associated With Invasion and Progression in Non-Small Cell Lung Cancer.
    Wang Q; He Y; Li W; Xu X; Hu Q; Bian Z; Xu A; Tu H; Wu M; Wu X
    Front Immunol; 2022; 13():887916. PubMed ID: 35874720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer.
    Vanguri R; Benhamida J; Young JH; Li Y; Zivanovic O; Chi D; Snyder A; Hollmann TJ; Mager KL
    Gynecol Oncol Rep; 2022 Feb; 39():100926. PubMed ID: 35146104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
    Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
    PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Down-regulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in a murine breast cancer model.
    Sadighi S; Sharifian R; Kazemimanesh M; Muhammadnejad A; Shahosseini Z; Amanpour S; Muhammadnejad S
    Iran J Basic Med Sci; 2021 Apr; 24(4):537-544. PubMed ID: 34094037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.
    Wang Q; Zhang J; Tu H; Liang D; Chang DW; Ye Y; Wu X
    J Immunother Cancer; 2019 Nov; 7(1):334. PubMed ID: 31783776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-cell immunophenotyping revealed the association of CD4+ central and CD4+ effector memory T cells linking exacerbating chronic obstructive pulmonary disease and NSCLC.
    Gémes N; Balog JÁ; Neuperger P; Schlegl E; Barta I; Fillinger J; Antus B; Zvara Á; Hegedűs Z; Czimmerer Z; Manczinger M; Balogh GM; Tóvári J; Puskás LG; Szebeni GJ
    Front Immunol; 2023; 14():1297577. PubMed ID: 38187374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study.
    Botticelli A; Zizzari IG; Scagnoli S; Pomati G; Strigari L; Cirillo A; Cerbelli B; Di Filippo A; Napoletano C; Scirocchi F; Rughetti A; Nuti M; Mezi S; Marchetti P
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
    Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
    Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study.
    Skertich NJ; Chu F; Tarhoni IA; Szajek S; Borgia JA; Madonna MB
    Surg Open Sci; 2021 Oct; 6():10-14. PubMed ID: 34386763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer.
    Kozłowski M; Borzyszkowska D; Cymbaluk-Płoska A
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy.
    Grandal B; Mangiardi-Veltin M; Laas E; Laé M; Meseure D; Bataillon G; El-Alam E; Darrigues L; Dumas E; Daoud E; Vincent-Salomon A; Talagrand LS; Pierga JY; Reyal F; Hamy AS
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
    Wang H; Mao L; Zhang T; Zhang L; Wu Y; Guo W; Hu J; Ju H; Ren G
    J Oral Pathol Med; 2019 Sep; 48(8):669-676. PubMed ID: 31132187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment.
    Ziogas DC; Theocharopoulos C; Lialios PP; Foteinou D; Koumprentziotis IA; Xynos G; Gogas H
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
    Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
    Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Significance of Expression of Immunoadjuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer.
    Asano Y; Kashiwagi S; Takada K; Ishihara S; Goto W; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
    Anticancer Res; 2022 Jan; 42(1):125-136. PubMed ID: 34969718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
    Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
    World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging targets in cancer immunotherapy.
    Burugu S; Dancsok AR; Nielsen TO
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):39-52. PubMed ID: 28987965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy.
    Alhesa A; Awad H; Bloukh S; Al-Balas M; El-Sadoni M; Qattan D; Azab B; Saleh T
    Int J Immunopathol Pharmacol; 2022; 36():3946320221078433. PubMed ID: 35225058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.